TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

Download as PDF

The collaborative center will help to lower barriers to RNA innovation and discovery

SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.

TriLink’s investment includes direct funding for the center and access to TriLink’s proprietary in vitro transcription technology, CleanScript™, which will enable Hopkins researchers to advance mRNA development. Additionally, TriLink will provide technical expertise and access to other critical discovery and manufacturing supplies, further lowering the barriers to discovery and application.

“The collaboration with Johns Hopkins reinforces our commitment to advancing nucleic acid-based therapies,” commented Drew Burch, President, Nucleic Acid Products, Maravai LifeSciences. “Our participation in this center of excellence allows TriLink to share its deep knowledge and expertise in nucleic acid production, helping to enable these researchers at Hopkins with the tools they need to develop advanced therapies to treat patients."

According to Ed Schlesinger, dean of the Whiting School of Engineering, the aspiration for this center is the transformation of human health through the development of breakthroughs in RNA applications. Schlesinger adds that the availability of cutting-edge discovery tools will enable Johns Hopkins to grow its RNA research community and increase the cycle of innovation on campus.

Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics and a leader in messenger RNA stability and translation will serve as the inaugural director of the center, which will be anchored in the Institute of NanoBioTechnology (INBT) and open this spring. The center will bring together Johns Hopkins experts in RNA biology, genetic medicine, drug delivery, and biotechnology under one roof, serving as a training center for the next generation of RNA investigators and as a one-university nexus for RNA researchers across the various schools.

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

For more information, visit trilinkbiotech.com

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit maravai.com

Media Contact:
Liz Robinson of CG Life
TriLink BioTechnologies
+1 312-997-2436
lrobinson@cglife.com

Investor Contact:
Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com

Source: TriLink BioTechnologies

Released May 13, 2024